title: An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele.
abstract: Melanocytic nevi are the most potent risk factors for melanoma yet identified. Variation in the nevus phenotype within a population is predominantly genetically determined. Genes that determine nevus expression may therefore act as low penetrance melanoma susceptibility genes. Rare germline mutations in CDKN2A predispose to melanoma and appear to be nevogenic, although the correlation between nevus phenotype and mutation status is poor. It is plausible that more common CDKN2A variants may influence both melanoma susceptibility and nevus susceptibility. Ala148Thr is a G to A missense polymorphism of CDKN2A, which is found in 4%-6% of the general population. We have investigated the role of Ala148Thr as a low penetrance melanoma or nevus susceptibility allele in two separate groups of individuals. The first was a sample of 488 adults recruited from 179 families of patients with the atypical nevus phenotype and/or a family history of melanoma, and the second was a population-based sample of 599 women. Similar prevalences of Ala148Thr (4.9% and 5.2%) were found in both samples but significant variation in the prevalence of the polymorphism was seen across geographic areas within England. There was no association between Ala148Thr status and nevus number or history of melanoma, and therefore the results did not support the hypothesis that the Ala148Thr variant is a low penetrance melanoma or nevus susceptibility allele. A significant protective role of Ala148Thr on the number of atypical nevi was observed in the family sample (mean of 1 atypical nevus in those with the allele and 3.5 nevi in those without, p = 0.02). After allowing for potential confounders this was not evident in the population-based sample.
authors.affiliation: Division of Genetic Epidemiology, Cancer Research UK Clinical Center in Leeds, St. James's University Hospital, Leeds, U.K.
authors.forename: Chandra G
authors.initials: CG
authors.lastname: Bertram
authors.forename: Rupert M
authors.initials: RM
authors.lastname: Gaut
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Barrett
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Pinney
authors.forename: Linda
authors.initials: L
authors.lastname: Whitaker
authors.forename: Faye
authors.initials: F
authors.lastname: Turner
authors.forename: Veronique
authors.initials: V
authors.lastname: Bataille
authors.forename: Isabel
authors.initials: I
authors.lastname: Dos Santos Silva
authors.forename: Anthony
authors.initials: A
authors.lastname: J  Swerdlow
authors.forename: D Timothy
authors.initials: DT
authors.lastname: Bishop
authors.forename: Julia A
authors.initials: JA
authors.lastname: Newton Bishop
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D005260:Female; D019942:Genes, p16; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000235:genetics*; D008875:Middle Aged; D009506:Nevus / Q000235:genetics*; D011110:Polymorphism, Genetic